Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Secondary
1.6.1.1 Paid sources
1.6.1.2 Public sources
1.6.2 Primary
Chapter 2 Executive Summary
2.1 Pain management drugs market 360º synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Region trends
2.1.3 Drug class trends
2.1.4 Indication trends
2.1.5 Pain type trends
2.1.6 Distribution channel trends
Chapter 3 Pain Management Drugs Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rise in incidences of chronic pain
3.2.1.2 Increasing number of surgical procedures
3.2.1.3 Increasing demand for non-opioid analgesics
3.2.1.4 Increase in geriatric population
3.2.1.5 Favorable regulatory scenario
3.2.1.6 Technological advancements in drug delivery
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects and safety concerns
3.2.2.2 Patent expirations and generic competition
3.2.2.3 Availability of alternative therapies and non-pharmacological approaches
3.2.2.4 High development costs and lengthy approval processes
3.3 Growth potential analysis
3.3.1 By drug class
3.3.2 By indication
3.3.3 By pain type
3.3.4 By distribution channel
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Global company market share analysis, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Pain Management Drugs Market Estimates and Forecast, By Drug Class (USD Million)
5.1 Key trends, by drug class
5.2 NSAIDS
5.3 Anesthetics
5.4 Anticonvulsants
5.5 Antimigraine drugs
5.6 Antidepressant drugs
5.7 Opioids
5.8 Non-narcotic analgesics
5.9 Other drugs
Chapter 6 Pain Management Drugs Market Estimates and Forecast, By Indication (USD Million)
6.1 Key trends, by indication
6.2 Arthritic pain
6.3 Neuropathic pain
6.4 Cancer pain
6.5 Chronic back pain
6.6 Post-operative pain
6.7 Migraine
6.8 Fibromyalgia
6.9 Bone fracture
6.10 Muscle sprain/strain
6.11 Acute appendicitis
6.12 Other indications
Chapter 7 Pain Management Drugs Market Estimates and Forecast, By Pain Type (USD Million)
7.1 Key trends, by pain type
7.2 Chronic pain
7.3 Acute pain
Chapter 8 Pain Management Drugs Market Estimates and Forecast, By Distribution Type (USD Million)
8.1 Key trends, by distribution channel
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Pain Management Drugs Market Estimates and Forecast, By Region (USD Million)
9.1 North America
9.1.1 U.S.
9.1.2 Canada
9.2 Europe
9.2.1 Germany
9.2.2 UK
9.2.3 France
9.2.4 Spain
9.2.5 Italy
9.2.6 Rest of Europe
9.3 Asia Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Australia
9.3.5 Rest of Asia Pacific
9.4 Latin America
9.4.1 Brazil
9.4.2 Mexico
9.4.3 Rest of Latin America
9.5 Middle East & Africa
9.5.1 South Africa
9.5.2 Saudi Arabia
9.5.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 ENDO HEALTH SOLUTIONS, INC.
10.2 Merck & Co., Inc.
10.3 Novartis AG
10.4 Pfizer, Inc.
10.5 Sanofi S.A.
10.6 Mylan N.V.
10.7 Teva Pharmaceutical Industries Ltd.
10.8 Ely Lilly and Company
10.9 Abbott Laboratories
10.10 Purdue Pharma L.P.
10.11 GlaxoSmithKline Plc
10.12 Johnson & Johnson
10.13 F. Hoffmann La Roche Ltd.
